Original Paper

Predictive Performance of Machine Learning–Based Models for Poststroke Clinical Outcomes in Comparison With Conventional Prognostic Scores: Multicenter, Hospital-Based Observational Study

Fumi Irie<sup>1,2\*</sup>, MD, PhD; Koutarou Matsumoto<sup>3\*</sup>, MPH, PhD; Ryu Matsuo<sup>1,2</sup>, MD, PhD; Yasunobu Nohara<sup>4</sup>, PhD; Yoshinobu Wakisaka<sup>2</sup>, MD, PhD; Tetsuro Ago<sup>2,5</sup>, MD, PhD; Naoki Nakashima<sup>6</sup>, MD, PhD; Takanari Kitazono<sup>2,5</sup>, MD, PhD; Masahiro Kamouchi<sup>1,5</sup>, MD, PhD<sup>‡</sup>

<sup>1</sup>Department of Health Care Administration and Management, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan

<sup>‡</sup>Fukuoka Stroke Registry Investigators

\*these authors contributed equally

# **Corresponding Author:**

Masahiro Kamouchi, MD, PhD Department of Health Care Administration and Management Graduate School of Medical Sciences Kyushu University 3-1-1 Maidashi Higashi-ku Fukuoka, 812-8582 Japan Phone: 81 92 642 6960 Email: <u>kamouchi.masahiro.736@m.kyushu-u.ac.jp</u>

# Abstract

**Background:** Although machine learning is a promising tool for making prognoses, the performance of machine learning in predicting outcomes after stroke remains to be examined.

**Objective:** This study aims to examine how much data-driven models with machine learning improve predictive performance for poststroke outcomes compared with conventional stroke prognostic scores and to elucidate how explanatory variables in machine learning–based models differ from the items of the stroke prognostic scores.

**Methods:** We used data from 10,513 patients who were registered in a multicenter prospective stroke registry in Japan between 2007 and 2017. The outcomes were poor functional outcome (modified Rankin Scale score >2) and death at 3 months after stroke. Machine learning–based models were developed using all variables with regularization methods, random forests, or boosted trees. We selected 3 stroke prognostic scores, namely, ASTRAL (Acute Stroke Registry and Analysis of Lausanne), PLAN (preadmission comorbidities, level of consciousness, age, neurologic deficit), and iScore (Ischemic Stroke Predictive Risk Score) for comparison. Item-based regression models were developed using the items of these 3 scores. The model performance was assessed in terms of discrimination and calibration. To compare the predictive performance of the data-driven model with that of the item-based model, we performed internal validation after random splits of identical populations into 80% of patients as a training set and 20% of patients as a test set; the models were developed in the training set and were validated in the test set. We evaluated the contribution of each variable to the models and compared the predictors used in the machine learning–based models with the items of the stroke prognostic scores.

<sup>&</sup>lt;sup>2</sup>Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan

<sup>&</sup>lt;sup>3</sup>Biostatistics Center, Graduate School of Medicine, Kurume University, Kurume, Japan

<sup>&</sup>lt;sup>4</sup>Big Data Science and Technology, Faculty of Advanced Science and Technology, Kumamoto University, Kumamoto, Japan

<sup>&</sup>lt;sup>5</sup>Center for Cohort Studies, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan

<sup>&</sup>lt;sup>6</sup>Medical Information Center, Kyushu University Hospital, Fukuoka, Japan

**Results:** The mean age of the study patients was 73.0 (SD 12.5) years, and 59.1% (6209/10,513) of them were men. The area under the receiver operating characteristic curves and the area under the precision-recall curves for predicting poststroke outcomes were higher for machine learning–based models than for item-based models in identical populations after random splits. Machine learning–based models also performed better than item-based models in terms of the Brier score. Machine learning–based models used different explanatory variables, such as laboratory data, from the items of the conventional stroke prognostic scores. Including these data in the machine learning–based models as explanatory variables improved performance in predicting outcomes after stroke, especially poststroke death.

**Conclusions:** Machine learning–based models performed better in predicting poststroke outcomes than regression models using the items of conventional stroke prognostic scores, although they required additional variables, such as laboratory data, to attain improved performance. Further studies are warranted to validate the usefulness of machine learning in clinical settings.

(JMIR AI 2024;3:e46840) doi: 10.2196/46840

#### **KEYWORDS**

brain infarction; outcome; prediction; machine learning; prognostic score

# Introduction

#### Background

Despite receiving the best available treatment, patients who have had a stroke may still experience disability or, in some cases, even face the risk of death [1,2]. Stroke clinicians try to predict patients' outcomes as accurately as possible because accurate prognoses are a prerequisite for therapeutic decisions. Various stroke prognostic scores have been developed to support clinicians in predicting poststroke outcomes [3-8]. Nevertheless, prognostic scores have some disadvantages: generally, they limit the number of variables for ease of use at the bedside, and their validity needs to be reappraised over time, as the scoring criteria may become outdated with rapid progress in stroke care [9].

Meanwhile, recent advances in information technology have enabled the collection of a large amount of health information on individual patients [10,11]. Machine learning is considered a promising tool for improving the prediction accuracy of clinical outcomes for individual patients with stroke because of the ability of machine learning to deal with large and complex data [12-24].

However, several papers questioning the incremental value of machine learning have recently been published [25-27]. One study reported that machine learning algorithms did not perform better than traditional regression models for making prognoses in traumatic brain injury and recommended replicating studies in fields other than traumatic brain injury to ensure the generalizability of the findings [26]. Hitherto, few studies have directly compared the performance of data-driven models developed using machine learning methods and regression models based on conventional stroke prognostic scores in the field of outcome prediction after ischemic stroke [19,20,23]. In addition, calibration has not been adequately addressed in previous studies, and model performance has primarily been evaluated based on its discriminative ability [18-20].

#### Objectives

XSL•FC RenderX

In this study, we aimed to examine whether machine learning can improve the predictive performance for poststroke outcomes beyond preexisting stroke prognostic scores. We also sought to

```
https://ai.jmir.org/2024/1/e46840
```

elucidate the pattern of variables selected by machine learning algorithms to predict poststroke clinical outcomes. To this end, we analyzed the data of patients with acute ischemic stroke enrolled in a multicenter, hospital-based, prospective registry of stroke in Japan. We used 3 stroke prognostic scores, namely, Acute Stroke Registry and Analysis of Lausanne (ASTRAL) score [6], preadmission comorbidities, level of consciousness, age, and neurologic deficit (PLAN) score [7], and Ischemic Stroke Predictive Risk Score (iScore) [4,5], to create item-based regression models. We then compared the predictive performance of data-driven models developed using machine learning algorithms with that of item-based models in identical study populations. We also examined the explanatory variables used in data-driven models and compared them with the items of the conventional prognostic scores.

# Methods

#### **Ethical Considerations**

The study protocol was approved by the institutional review boards of all hospitals (Kyushu University Institutional Review Board for Clinical Research: 22086-01; Kyushu Medical Center Institutional Review Board: R06-03; Clinical Research Review Board of Fukuokahigashi Medical Center: 29-C-38; Fukuoka Red Cross Hospital Institutional Review Board: 629; St Mary's Hospital Research Ethics Review Committee: S13-0110; Steel Memorial Yawata Hospital Ethics Committee: 06-04-13; and Kyushu Rosai Hospital Institutional Review Board: 21-8). Written informed consent was obtained from all patients or their family members.

#### **Data Source**

We used data from the Fukuoka Stroke Registry (FSR), a multicenter, hospital-based, prospective registry of patients with acute stroke. FSR enrolled patients with stroke hospitalized in 7 participating hospitals in Fukuoka, Japan, within 7 days of onset (University Hospital Medical Information Network Clinical Trial Registry: UMIN000000800). Details of the registry have been previously published [28,29]. In FSR, clinical data during routine stroke care in the hospitals were recorded along with baseline information on variables such as demographics, prior history, comorbidity, and functional level

before stroke onset. The definitions of these variables have been previously described [28,29].

### **Stroke Prognostic Scores**

The conventional stroke prognostic scores were used for comparison against data-driven prediction models. In this study, we selected prognostic scores based on the following criteria: they are multiitem and point-based scores using demographic and clinical information, they were developed to predict short-term outcomes after ischemic stroke, and they were externally validated. Consequently, 3 stroke prognostic scores, the ASTRAL score [6], PLAN score [7], and iScore [4,5], were used for comparative analysis. Items of these preexisting stroke prognostic scores were used as explanatory variables in item-based models (Multimedia Appendix 1).

### **Study Populations**

FSR included 10,700 consecutive patients with acute ischemic stroke who were registered between June 2007 and May 2017.

Ischemic stroke was diagnosed based on the sudden onset of a nonconvulsive and focal neurological deficit confirmed by brain imaging through computed tomography, magnetic resonance imaging, or both conducted upon admission. Of the 10,700 patients, 187 (1.7%) were lost to follow-up, and the remaining 10,513 (98.3%) were analyzed for 3 months post stroke.

Study patients were selected according to the inclusion and exclusion criteria of preexisting stroke prognostic scores to make the study populations identical between the item-based and machine learning–based models (Multimedia Appendix 2). Furthermore, we limited the study to patients with complete data, ensuring there were no missing variables across all data points. This approach aimed to prevent further reduction in the number of analyzed patients owing to list-wise deletion in regression models. The frequency of missing data is shown in Multimedia Appendix 3. Consequently, population 1, population 2, and population 3 were included in the analysis for comparison with the ASTRAL score, PLAN score, and iScore, respectively. Figure 1 illustrates the patient selection in each population.

**Figure 1.** Flowchart for the selection of study patients. Study patients were selected according to the inclusion and exclusion criteria used in the original studies of 3 stroke prognostic scores: population 1 for the Acute Stroke Registry and Analysis of Lausanne (ASTRAL) score, population 2 for the preadmission comorbidities, level of consciousness, age, and neurologic deficit (PLAN) score, and population 3 for the Ischemic Stroke Predictive Risk Score (iScore). Patients with missing data on explanatory variables were excluded from the analyses of data-driven models to avoid the influence of list-wise deletion.



# **Study Outcomes**

The study outcomes were poor functional outcome and death at 3 months after stroke. Poor functional outcome was defined as a modified Rankin Scale score >2 at 3 months after stroke onset [30]. Death was defined as death from any cause within

3 months after stroke [30]. Interviewers on clinical outcomes were blinded to the patients' backgrounds.

# **Development of Predictive Models**

We performed logistic regression analysis to develop item-based models using the predictors of the ASTRAL score, PLAN score,

and iScore as explanatory variables (Multimedia Appendix 1). The predictors used in these models included age, time delay from onset to admission, stroke scale score, decreased level of consciousness, visual field defect, and abnormal glucose levels for the ASTRAL score; age, atrial fibrillation, congestive heart failure, cancer, preadmission dependence, decreased level of consciousness, leg weakness, arm weakness, and aphasia or neglect for the PLAN score; age, male sex, atrial fibrillation, congestive heart failure, renal dialysis, cancer, preadmission dependence, Stroke subtype, and abnormal glucose levels for the iScore. The categorization of predictors in the stroke prognostic scores was the same as that used in the original study for each score.

We used regularization methods (ridge regression [RR] and least absolute shrinkage and selection operator [LASSO] regression models) and ensemble decision tree models (random forest [RF] and Extreme Gradient Boosting [XGBoost]) for data-driven models based on machine learning algorithms [31-34]. All available variables were included in the development of data-driven models (Multimedia Appendix 3). The details of the model development are presented in Multimedia Appendix 4.

### **Metrics of Model Performance**

The discriminative ability of each model was evaluated using the area under the receiver operating characteristic curve (AUROC) and the area under the precision-recall curve (AUPRC). AUPRC was calculated because it is a useful performance metric for unbalanced data of infrequent outcome events, such as death [35].

The calibration of each model was assessed using a calibration plot. Calibration plots were obtained by plotting the predicted

and observed probabilities of the clinical outcomes in the 10 risk groups estimated using each predictive model. The Brier score was also used to assess the overall performance. The Brier score is defined as  $1/N \sum_{i=1}^{N} (pi-ai)^2$ ,  $(0 \le BS \le 1)$ , where pi is the predicted probability of the occurrence of an event ranging from 0 to 1, ai indicates the event with binary outcomes (1 for observed or 0 for not observed), and N is the number of samples.

### Validation and Comparison of Models

We performed internal validation of item-based and data-driven models after 100 repeated random splits into 80% of the patients as a training set and 20% of patients as a test set (Figure 2). The parameters in the training set were optimally tuned via 10-fold cross-validation in the data-driven models. After 100 random splits, the predictive models were developed by logistic regression using the items of the stroke prognostic scores (item-based model) and by machine learning using all variables (data-driven model) in the training set. The developed item-based and data-driven models were validated in the test set. The data sets for both training and testing were identical for the item-based and data-driven models. The median and 95% CI of the performance metrics, that is, AUROC, AUPRC, and Brier score, were calculated for each model using the results of the 100 repeated random splits. To directly compare the performance of the item-based and data-driven models (RR, LASSO, RF, and XGBoost), we compared the AUROC, AUPRC, and Brier score of the data-driven models with those of the corresponding item-based model. We repeated the comparison 100 times and calculated the times that the AUROC, AUPRC, and Brier score of data-driven models were better than those of the corresponding item-based model among the 100 repetitions.



#### Irie et al

**Figure 2.** Schematic diagram of the development and validation of the predictive models. All patients were randomly split into 80% of the development cohort as training data and 20% of the validation cohort as test data, which was repeated 100 times. Among the data-driven models, predictive models were developed based on ridge regression (RR), least absolute shrinkage and selection operator regression (LASSO), random forest (RF), and Extreme Gradient Boosting (XGBoost) using all available data after hyperparameter tuning in the development cohort. Logistic regression was used with predictors of stroke prognostic scores in the item-based models. The predictive models were validated using the test data of the validation cohort. In each split, the training and test data were identical between the data-driven and item-based models. ASTRAL: Acute Stroke Registry and Analysis of Lausanne; PLAN: preadmission comorbidities, level of consciousness, age, and neurologic deficit.



### **Evaluation of the Contribution of Variables**

We evaluated the importance of the variables used in the item-based and data-driven models. To assess the contribution of each predictor to the item-based regression model, we calculated the rate of times when the association between each variable and clinical outcomes was statistically significant (P<.05) after 100 random splits. In the machine learning models, the magnitude of variable importance was evaluated in identical populations after 100 random splits (Multimedia Appendix 4).

We calculated the AUROC of the XGBoost model using various types of variables to assess how the addition of explanatory variables improves the predictive performance of the data-driven model. First, we constructed a model with age, sex, National Institutes of Health Stroke Scale (NIHSS) score, and preadmission modified Rankin Scale score (model 1). Then, 5 models were developed by adding items relating to preadmission status to model 1 (model 2), items relating to clinical data on admission to model 2 (model 3), items relating to brain imaging data to model 3 (model 4), and items relating to laboratory data to model 4 (model 5).

# **Statistical Analysis**

We used the chi-square test, 2-tailed Student t test, or Mann-Whitney U test to compare the differences in baseline characteristics and clinical data, as appropriate [36]. Two-sided P values <.05 were considered statistically significant. All statistical analyses were performed using the R statistical package (R Development Core Team). This study was conducted in accordance with the Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis (TRIPOD) initiative [37].

# Results

### **Baseline Variables and Clinical Outcomes**

The mean age of the 10,513 patients was 73.0 (SD 12.5) years, and 59.1% (6209/10,513) of the patients were men. At 3 months after stroke, a poor functional outcome was found in 1204 (31.4%) of 3832 patients in population 1, 2209 (35.9%) of 6154 patients in population 2, and 2540 (37.1%) of 6855 patients in population 3. Within 3 months after stroke onset, 3% (113/3832), 3.6% (219/6154), and 3.7% (255/6855) of the patients died in population 1, population 2, and population 3, respectively.

First, we investigated the differences in the predictors of preexisting point-based stroke prognostic scores among patients according to poststroke clinical outcomes. Consequently, almost all variables significantly (P<.05) differed depending on the 3-month functional outcome (Table 1) and 3-month survival status (Multimedia Appendix 5) in addition to the predictors used in preexisting prognostic scores.



 Table 1. Baseline data according to functional outcome at 3 months.

Demographics         73.0 (12.5)         68.9 (12.0)         79.4 (10.4)         <.001
Age (y), mean (SD)       73.0 (12.5)       68.9 (12.0)       79.4 (10.4)       <.001
Men, n (%)       6209 (59.1)       4257 (66.5)       1952 (47.5)       <.001
Risk factors, n (%)       Hypertension       8485 (80.7)       5138 (80.2)       3347 (81.5)       .11         Diabetes mellitus       3607 (34.3)       2236 (34.9)       1371 (33.4)       .11         Atrial fibrillation       2743 (26.1)       1173 (18.3)       1570 (38.3)       <001
Hypertension       8485 (80.7)       5138 (80.2)       3347 (81.5)       .11         Diabetes mellitus       3607 (34.3)       2236 (34.9)       1371 (33.4)       .11         Atrial fibrillation       2743 (26.1)       1173 (18.3)       1570 (38.3)       <.001
Diabetes mellitus       3607 (34.3)       2236 (34.9)       1371 (33.4)       .11         Atrial fibrillation       2743 (26.1)       1173 (18.3)       1570 (38.3)       <.001
Atrial fibrillation       2743 (26.1)       1173 (18.3)       1570 (38.3)       <.001
Smoking       2261 (23.1)       1717 (28.9)       544 (14.2)       <.001         Comorbid conditions, n (%)           <.001         Congestive heart failure       919 (8.7)       423 (6.6)       496 (12.1)       <.001         Kidney disease on dialysis       332 (3.2)       171 (2.7)       161 (3.9)       <.001         Cancer       1552 (14.8)       774 (12.1)       778 (18.9)       <.001         Previous history, n (%)          <.001         Previous myocardial infarction       505 (5.3)       242 (4.3)       263 (6.9)       <.001         Preadmission functional status           <.001
Comorbid conditions, n (%)       Congestive heart failure       919 (8.7)       423 (6.6)       496 (12.1)       <.001
Congestive heart failure       919 (8.7)       423 (6.6)       496 (12.1)       <.001
Kidney disease on dialysis       332 (3.2)       171 (2.7)       161 (3.9)       <.001         Cancer       1552 (14.8)       774 (12.1)       778 (18.9)       <.001         Previous history, n (%)       242 (4.3)       263 (6.9)       <.001         Preadmission functional status       0 (0-1)       0 (0-0)       1 (0.3)       <001
Cancer       1552 (14.8)       774 (12.1)       778 (18.9)       <.001         Previous history, n (%)
Previous history, n (%)         242 (4.3)         263 (6.9)         <.001           Preadmission functional status          0 (0-1)         0 (0-0)         1 (0.3)         < 001
Previous myocardial infarction       505 (5.3)       242 (4.3)       263 (6.9)       <.001
Preadmission functional status Preadmission mRS median (IOR) $0(0-1)$ $0(0-0)$ $1(0,3)$ < 001
Preadmission mRS median (IOR) $0.0-1$ $0.0-0$ $1.0.2$ $-0.01$
1 (0.3) = 1 (0
Preadmission dependence (mRS score >1), n (%)         2366 (22.5)         364 (5.7)         2002 (48.7)         <.001
Onset-to-admission time, n (%) <.001
$\leq 1 h$ 943 (9) 490 (7.7) 453 (11)
$\leq 3 h$ 1469 (14) 771 (12) 698 (17)
≤6 h 1141 (10.9) 644 (10.1) 497 (12.1)
≤24 h 3515 (33.4) 2090 (32.6) 1425 (34.7)
>24 h 3445 (32.8) 2410 (37.6) 1035 (25.2)
Stroke subtype, n (%) <.001
Small vessel occlusion2119 (20.2)1724 (26.9)395 (9.6)
Large artery atherosclerosis1823 (17.3)1006 (15.7)817 (19.9)
Cardioembolism 2496 (23.7) 1054 (16.5) 1442 (35.1)
Other determined etiology         2146 (20.4)         1404 (21.9)         742 (18.1)
Undetermined1929 (18.3)1217 (19)712 (17.3)
Neurological severity, median (IQR) or n (%)
NIHSS <sup>b</sup> score 3 (2-8) 2 (1-4) 8 (4-16) <.001
Severe stroke (NIHSS score >10) 1938 (18.4) 291 (4.5) 1647 (40.1) <.001
Neurological deficits, n (%)
Decreased level of consciousness         3129 (30)         770 (12.1)         2359 (57.9)         <.001
Leg weakness 5394 (51.9) 2357 (37.2) 3037 (75) <.001
Arm weakness5634 (54.2)2520 (39.7)3114 (76.8)<.001
Aphasia or neglect         2912 (27.9)         946 (14.9)         1966 (48.3)         <.001
Visual field defect         999 (9.6)         447 (7.0)         552 (13.6)         <.001
Physiological data, mean (SD)
SBP <sup>c</sup> , mm Hg 86.6 (18.2) 87.9 (17.8) 84.6 (18.6) <.001
DBP <sup>d</sup> , mm Hg 159.8 (29.3) 160.4 (28.6) 158.8 (30.3) .01

https://ai.jmir.org/2024/1/e46840

XSL•FO RenderX JMIR AI 2024 | vol. 3 | e46840 | p. 6 (page number not for citation purposes)

	Overall (n=10,513)	mRS <sup>a</sup> 0-2 (n=6405)	mRS 3-6 (n=4108)	P value
BMI, kg/m <sup>2</sup>	22.8 (3.8)	23.5 (3.6)	21.7 (3.9)	<.001
Laboratory data, median (IQR)				
Complete blood cell count				
WBC <sup>e</sup> $(10^3/\mu L)$	6.8 (5.6-8.4)	6.7 (5.5-8.2)	7.0 (5.7-8.9)	<.001
$RBC^{f}(10^{4}/\mu L)$	436 (394-476)	449 (411-485)	416 (372-458)	<.001
Hematocrit (%)	40.1 (36.5-43.4)	41.1 (37.9-44.0)	38.2 (34.6-41.9)	<.001
Hemoglobin (g/dL)	13.5 (12.1-14.8)	14.0 (12.7-15.1)	12.8 (11.4-14.1)	<.001
Platelet (10 <sup>4</sup> /µL)	20.2 (16.6-24.3)	20.6 (17.0-24.7)	19.5 (15.8-23.6)	<.001
Liver function				
AST <sup>g</sup> (U/L)	23 (19-29)	23 (19-29)	23 (19-30)	.001
ALT <sup>h</sup> (U/L)	17 (12-24)	18 (13-25)	15 (11-22)	<.001
LDH <sup>i</sup> (U/L)	219 (186-266)	211 (181-254)	230 (195-285)	<.001
ALP <sup>j</sup> (U/L)	239 (195-295)	231 (190-284)	250 (203-312)	<.001
Kidney function				
BUN <sup>k</sup> (mg/dL)	16.0 (13.0-20.9)	15.3 (12.6-19.0)	17.9 (13.8-23.8)	<.001
Creatinine (mg/dL)	0.8 (0.6-1.0)	0.8 (0.7-1.0)	0.8 (0.6-1.1)	<.001
eGFR <sup>1</sup> (mL/min/1.73 m <sup>2</sup> )	66.5 (51.2-81.5)	70.2 (55.9-83.8)	60.8 (44.8-76.5)	<.001
Glycemic control				
Glucose (mg/100 mL)	121 (103-156)	119 (103-154)	124 (105-158)	.001
Hemoglobin $A_{1c}$ (%)	5.9 (5.6-6.6)	5.9 (5.6-6.6)	5.9 (5.5-6.5)	<.001
Inflammation				
hsCRP <sup>m</sup> , mg/dL	1.5 (0.5-6.1)	1.0 (0.4-2.9)	3.9 (1.0-16.3)	<.001
Coagulation				
PT-INR <sup>n</sup>	1.0 (1.0-1.1)	1.0 (1.0-1.1)	1.1 (1.0-1.1)	<.001
APTT <sup>0</sup> (s)	29.7 (27.2-32.7)	29.5 (27.1-32.4)	30.1 (27.3-33.3)	<.001
Fibrinogen (mg/dL)	304 (260-359)	297 (256-349)	315 (267-375)	<.001
d-dimer (µg/mL)	0.9 (0.4-2.0)	0.6 (0.2-1.2)	1.7 (0.9-4.0)	<.001

<sup>a</sup>mRS: modified Rankin Scale.

.

<sup>b</sup>NIHSS: National Institutes of Health Stroke Scale.

<sup>c</sup>SBP: systolic blood pressure.

<sup>d</sup>DBP: diastolic blood pressure.

<sup>e</sup>WBC: white blood cell count.

<sup>f</sup>RBC: red blood cell count.

<sup>g</sup>AST: aspartate aminotransferase.

<sup>h</sup>ALT: alanine aminotransferase.

<sup>i</sup>LDH: lactate dehydrogenase.

<sup>j</sup>ALP: alkaline phosphatase.

<sup>k</sup>BUN: blood urea nitrogen.

<sup>l</sup>eGFR: estimated glomerular filtration rate.

<sup>m</sup>hsCRP: high-sensitivity C-reactive protein.

<sup>n</sup>PT-INR: international normalized ratio of prothrombin time.

<sup>o</sup>APTT: activated partial thromboplastin time.

# **Assessment of Model Performance**

AUROCs varied depending on study populations, whereas differences between the machine learning algorithms were minimal in the same study population and for the same outcome. The AUROCs of data-driven models based on machine learning were generally higher than those of item-based models for predicting both 3-month poor functional outcome and all-cause death (Table 2). Similarly, AUPRCs were generally higher in data-driven models than in item-based models for predicting both poor functional outcome and all-cause death (Table 3). Regarding the Brier score, the data-driven models performed better than the item-based models (Table 4).

**Table 2.** Area under the receiver operating characteristic curve for predicting unfavorable clinical outcomes at 3 months using item-based and data-driven models<sup>a</sup>.

	Item-based model, median (95% CI)	Data-driven models, median (95% CI)				
		RR <sup>b</sup>	LASSO <sup>c</sup>	RF <sup>d</sup>	XGBoost <sup>e</sup>	
Poor functional outcome						
Population 1 (n=3832)	0.83 (0.80-0.85)	0.86 (0.83-0.89)	0.86 (0.84-0.89)	0.86 (0.84-0.88)	0.86 (0.83-0.89)	
Population 2 (n=6154)	0.88 (0.86-0.90)	0.91 (0.90-0.93)	0.91 (0.90-0.93)	0.91 (0.89-0.92)	0.91 (0.89-0.93)	
Population 3 (n=6855)	0.87 (0.85-0.89)	0.90 (0.89-0.92)	0.90 (0.89-0.92)	0.90 (0.88-0.91)	0.90 (0.89-0.92)	
Death						
Population 1 (n=3832)	0.77 (0.69-0.87)	0.87 (0.79-0.93)	0.87 (0.78-0.92)	0.89 (0.81-0.93)	0.88 (0.82-0.93)	
Population 2 (n=6154)	0.84 (0.80-0.89)	0.89 (0.85-0.92)	0.88 (0.84-0.92)	0.90 (0.86-0.93)	0.90 (0.86-0.93)	
Population 3 (n=6855)	0.82 (0.77-0.87)	0.88 (0.84-0.91)	0.87 (0.83-0.90)	0.89 (0.86-0.92)	0.89 (0.85-0.91)	

<sup>a</sup>The study populations were selected according to the inclusion and exclusion criteria for the Acute Stroke Registry and Analysis of Lausanne (ASTRAL) score (population 1), the preadmission comorbidities, level of consciousness, age, and neurologic deficit (PLAN) score (population 2), and the Ischemic Stroke Predictive Risk Score (iScore; population 3).

<sup>b</sup>RR: ridge regression.

<sup>c</sup>LASSO: least absolute shrinkage and selection operator regression.

<sup>d</sup>RF: random forest.

<sup>e</sup>XGBoost: Extreme Gradient Boosting.

Table 3. Area under the precision-recall curve for predicting unfavorable clinical outcomes at 3 months using item-based and data-driven models<sup>a</sup>.

	Item-based model, median (95% CI)	Data-driven models, median (95% CI)			
		RR <sup>b</sup>	LASSO <sup>c</sup>	$RF^d$	XGBoost <sup>e</sup>
Poor functional outcome			·	·	
Population 1 (n=3832)	0.71 (0.66-0.75)	0.75 (0.71-0.79)	0.75 (0.71-0.80)	0.74 (0.69-0.79)	0.75 (0.71-0.79)
Population 2 (n=6154)	0.83 (0.80-0.86)	0.87 (0.85-0.89)	0.87 (0.85-0.90)	0.87 (0.84-0.89)	0.87 (0.85-0.89)
Population 3 (n=6855)	0.83 (0.80-0.85)	0.87 (0.85-0.89)	0.87 (0.85-0.89)	0.86 (0.84-0.88)	0.87 (0.85-0.89)
Death					
Population 1 (n=3832)	0.11 (0.06-0.24)	0.17 (0.08-0.32)	0.17 (0.07-0.31)	0.26 (0.13-0.44)	0.24 (0.12-0.39)
Population 2 (n=6154)	0.17 (0.11-0.25)	0.27 (0.18-0.37)	0.27 (0.18-0.38)	0.29 (0.18-0.42)	0.27 (0.16-0.35)
Population 3 (n=6855)	0.18 (0.11-0.25)	0.27 (0.16-0.36)	0.27 (0.17-0.38)	0.29 (0.19-0.42)	0.28 (0.19-0.39)

<sup>a</sup>The study populations were selected according to the inclusion and exclusion criteria for the Acute Stroke Registry and Analysis of Lausanne (ASTRAL) score (population 1), the preadmission comorbidities, level of consciousness, age, and Neurologic deficit (PLAN) score (population 2), and the Ischemic Stroke Predictive Risk Score (iScore; population 3).

<sup>b</sup>RR: ridge regression.

<sup>c</sup>LASSO: least absolute shrinkage and selection operator regression.

<sup>d</sup>RF: random forest.

<sup>e</sup>XGBoost: Extreme Gradient Boosting.

Table 4. Brier score for predicting unfavorable clinical outcomes at 3 months using item-based and data-driven models<sup>a</sup>.

	Item-based model, median (95% CI)	Data-driven models, median (95% CI)				
		RR <sup>b</sup>	LASSO <sup>c</sup>	RF <sup>d</sup>	XGBoost <sup>e</sup>	
Poor functional outcome						
Population 1 (n=3832)	0.15 (0.14-0.17)	0.14 (0.12-0.15)	0.14 (0.12-0.15)	0.14 (0.13-0.15)	0.14 (0.12-0.15)	
Population 2 (n=6154)	0.13 (0.12-0.14)	0.11 (0.10-0.12)	0.11 (0.10-0.12)	0.12 (0.11-0.13)	0.11 (0.10-0.12)	
Population 3 (n=6855)	0.13 (0.12-0.15)	0.12 (0.11-0.13)	0.12 (0.11-0.13)	0.12 (0.12-0.13)	0.12 (0.11-0.13)	
Death						
Population 1 (n=3832)	0.03 (0.02-0.03)	0.03 (0.02-0.03)	0.03 (0.02-0.03)	0.03 (0.02-0.03)	0.03 (0.02-0.03)	
Population 2 (n=6154)	0.03 (0.02-0.04)	0.03 (0.02-0.04)	0.03 (0.02-0.04)	0.03 (0.02-0.04)	0.03 (0.02-0.04)	
Population 3 (n=6855)	0.03 (0.02-0.04)	0.03 (0.02-0.04)	0.03 (0.02-0.04)	0.03 (0.02-0.04)	0.03 (0.02-0.04)	

<sup>a</sup>The study populations were selected according to the inclusion and exclusion criteria for the Acute Stroke Registry and Analysis of Lausanne (ASTRAL) score (population 1), the preadmission comorbidities, level of consciousness, age, and neurologic deficit (PLAN) score (population 2), and the Ischemic Stroke Predictive Risk Score (iScore; population 3).

<sup>b</sup>RR: ridge regression.

<sup>c</sup>LASSO: least absolute shrinkage and selection operator regression.

<sup>d</sup>RF: random forest.

<sup>e</sup>XGBoost: Extreme Gradient Boosting.

The predictive performance of data-driven models compared with the corresponding item-based model was examined by the frequency of the performance metrics (AUROC, AUPRC, and Brier score) of data-driven models, which were better than those of the corresponding item-based model in the identical training and test data sets after 100 repeated random splits (Table 5). Regarding poor functional outcome, the frequency exceeded 95% for all metrics in all the data-driven models (RR, LASSO, RF, and XGBoost), indicating that the probability of the worse performance of data-driven models compared with the item-based model was <5%. Regarding death, the frequency

was >95% for AUROC in all the data-driven models but did not always attain 95% for AUPRC or Brier score.

Calibration for predicting poor functional outcome was compared between the item-based and data-driven models (RR, LASSO, RF, and XGBoost) in population 1 for the ASTRAL score, in population 2 for the PLAN score, and in population 3 for the iScore. The prediction of poor functional outcome (Figure 3) and all-cause death (Figure 4) demonstrated concordance between the predicted and observed probabilities in the item-based models as well as in the data-driven models.



Table 5. Predictive performance of data-driven models versus item-based models<sup>a</sup>.

	Poor functional outcome			Death				
	RR <sup>b</sup>	LASSO <sup>c</sup>	$RF^d$	XGBoost <sup>e</sup>	RR	LASSO	RF	XGBoost
AUROC <sup>f</sup>								
Population 1 (n=3832)	100	100	100	100	97	95	97	96
Population 2 (n=6154)	100	100	100	100	100	100	98	99
Population 3 (n=6855)	100	100	100	100	100	99	100	99
AUPRC <sup>g</sup>								
Population 1 (n=3832)	100	100	99	98	81	78	93	93
Population 2 (n=6154)	100	100	100	100	99	99	99	100
Population 3 (n=6855)	100	100	100	100	98	98	100	98
Bier score								
Population 1 (n=3832)	100	100	99	100	83	70	96	89
Population 2 (n=6154)	100	100	100	100	98	92	97	93
Population 3 (n=6855)	100	100	100	100	100	99	100	96

<sup>a</sup>Data indicate the frequency that AUROC, AUPRC, and Brier score of data-driven models (RR, LASSO, RF, or XGBoost) exceeded those of item-based models in identical training and test sets after 100 repeated random splits.

<sup>b</sup>RR: ridge regression.

<sup>c</sup>LASSO: least absolute shrinkage and selection operator regression.

<sup>d</sup>RF: random forest.

<sup>e</sup>XGBoost: Extreme Gradient Boosting.

 ${}^{\rm f}\!AUROC$  area under the receiver operating characteristic curve.

<sup>g</sup>AUPRC: area under the precision-recall curve.



**Figure 3.** Calibration of item-based and data-driven models for predicting poor functional outcome. Calibration for predicting poor functional outcome was compared between the item-based regression model and data-driven models (ridge regression [RR], least absolute shrinkage and selection operator regression [LASSO], random forest [RF], and Extreme Gradient Boosting [XGBoost]) in population 1 for the Acute Stroke Registry and Analysis of Lausanne (ASTRAL) score, population 2 for the preadmission comorbidities, level of consciousness, age, and neurologic deficit (PLAN) score, and population 3 for the Ischemic Stroke Predictive Risk Score (iScore). The patients were categorized into 10 groups stratified by the predicted probability of poor functional outcome in the test data. Observed probabilities (x-axis) were plotted against predicted probabilities (y-axis) in the 10 groups based on risk stratification. The results for the first 100 random splits are presented.





#### Irie et al

**Figure 4.** Calibration of item-based and data-driven models for predicting death. Calibration for predicting death was compared between the item-based regression model and data-driven models (ridge regression [RR], least absolute shrinkage and selection operator regression [LASSO], random forest [RF], and Extreme Gradient Boosting [XGBoost]) in population 1 for the Acute Stroke Registry and Analysis of Lausanne (ASTRAL) score, population 2 for the preadmission comorbidities, level of consciousness, age, and neurologic deficit (PLAN) score, and population 3 for the Ischemic Stroke Predictive Risk Score (iScore). The patients were categorized into 10 groups stratified by the predicted probability of death in the test data. Observed probabilities (x-axis) were plotted against predicted probabilities (y-axis) in the 10 groups based on risk stratification. The results for the first 100 random splits are presented.



# **Evaluation of Variables**

Next, we evaluated how each variable contributed to the predictive performance of the item-based and data-driven models (RF and XGBoost) in population 1 (Figure 5), population 2 (Figure 6), and population 3 (Figure 7). The selected variables differed substantially between the study populations in the item-based models. Age, preadmission dependence, and neurological severity of stroke were important variables in predicting both poor functional outcome and death (Figures 5-7; left panels). Age and neurological deficit signs (arm or leg weakness and loss of consciousness) were the most frequently used variables for predicting poor functional outcome (Figures 5A, 6A, and 7A; middle and right panels) in RF and XGBoost.

In contrast, variables not used in the item-based models, such as d-dimer, high-sensitivity C-reactive protein, fibrinogen, and BMI, were the most frequently used variables by RF and XGBoost (Figures 5B, 6B, and 7B; middle and right panels) in predicting death.

We also investigated how the addition of variables increased the predictive performance of XGBoost. As a result, the AUROC for poor functional outcome did not substantially increase even when explanatory variables other than key predictors were added to model 1 (Figure 8; open circles). Conversely, the AUROC for all-cause death linearly increased with the addition of other variables to the models, particularly items from laboratory data (Figure 8; closed circles).



**Figure 5.** Comparison of variable importance between items of the Acute Stroke Registry and Analysis of Lausanne (ASTRAL) score and explanatory variables in machine learning model in population 1. The contribution of each variable to the models in predicting poor functional outcome (A) and death (B) is shown. The patients were selected based on the ASTRAL criteria (population 1). In item-based regression models, the percentage indicates the rate of times when its association with clinical outcomes was statistically significant (*P*<.05). In machine learning models, the top 10 variables are shown according to the magnitude of variable importance. Boxes, vertical lines in the boxes, and horizontal bars indicate IQR, median, and minimal or maximal range, respectively. NIHSS: National Institutes of Health Stroke Scale, hsCRP: high-sensitivity C-reactive protein, LOC: loss of consciousness, mRS: modified Rankin Scale, BMI: body mass index, WBC: white blood cell count, LDH: lactate dehydrogenase, HbA1c: hemoglobin A1c, Fib: fibrinogen, Plt: platelet count, RBC: red blood cell count, ALP: alkaline phosphatase, Ht: hematocrit, Hb: hemoglobin, BUN: blood urea nitrogen, LDH: lactate dehydrogenase, PT-INR: international normalized ratio of prothrombin time.



В





**Figure 6.** Comparison of variable importance between items of the preadmission comorbidities, level of consciousness, age, and neurologic deficit (PLAN) score and explanatory variables in machine learning model in population 2. The contribution of each variable to the models in predicting poor functional outcome (A) and death (B) is shown. The patients were selected based on the PLAN score criteria (population 2). In item-based regression models, the percentage indicates the rate of times when its association with clinical outcomes was statistically significant (*P*<.05). In machine learning models, the top 10 variables are shown according to the magnitude of variable importance. Boxes, vertical lines in the boxes, and horizontal bars indicate IQR, median, and minimal or maximal range, respectively. mRS: modified Rankin Scale, LOC: loss of consciousness, hsCRP: high-sensitivity C-reactive protein, BMI: body mass index, Hb: hemoglobin, WBC: white blood cell count, Plt: platelet count, Fib: fibrinogen, RBC: red blood cell count, LDH: lactate dehydrogenase, Ht: hematocrit, ALP: alkaline phosphatase, PT-INR: international normalized ratio of prothrombin time.





#### Irie et al

**Figure 7.** Comparison of variable importance between items of Ischemic Stroke Predictive Risk Score (iScore) and explanatory variables in machine learning model in population 3. The contribution of each variable to the models in predicting poor functional outcome (A) and death (B) is shown. The patients were selected according to the iScore criteria (population 3). In item-based regression models, the percentage indicates the rate of times when its association with clinical outcomes was statistically significant (*P*<.05). In machine learning models, the top 10 variables are shown according to the magnitude of variable importance. Boxes, vertical lines in the boxes, and horizontal bars indicate IQR, median, and minimal or maximal range, respectively. NIHSS: National Institutes of Health Stroke Scale, CNS: Canadian Neurological Scale, mRS: modified Rankin Scale, LOC: loss of consciousness, hsCRP: high-sensitivity C-reactive protein, BMI: body mass index, Hb: hemoglobin, WBC: white blood cell count, Fib: fibrinogen, RBC: red blood cell count, Plt: platelet count, Ht: hematocrit, LDH: lactate dehydrogenase, ALP: alkaline phosphatase, PT-INR: international normalized ratio of prothrombin time.

А



**Figure 8.** Improvement of discrimination in a data-driven model by adding different types of data. The area under the receiver operating characteristic curves (AUROCs) for predicting poor functional outcome (open circles) and death (closed circles) were compared among the 5 models, which used different types of variables. A data-driven model was developed for each population using Extreme Gradient Boosting. Vertical bars indicate the 95th percentile after 100 random splits. The variables used for the models were as follows: model 1: age, sex, National Institutes of Health Stroke Scale score, and preadmission modified Rankin Scale score; model 2: model 1 plus clinical data before admission (eg, risk factors, comorbid conditions, previous history, family history, and prestroke medication); model 3: model 2 plus clinical data on admission (eg, onset-to-admission time, ambulance use, BMI, and physiological data); model 4: model 3 plus brain imaging data (eg, site of lesion, side of lesion, and stroke subtype); and model 5: model 4 plus laboratory data.



# Discussion

# **Principal Findings**

This study, which analyzed comprehensive clinical data from a multicenter, hospital-based stroke registry, yielded the following major findings. The performance of item-based regression models using the predictors of 3 conventional stroke prognostic scores was fair in predicting clinical outcomes at 3 months after ischemic stroke in our cohort, despite differences in clinical and social backgrounds from the original cohorts of scores. Data-driven models based on machine learning algorithms exhibited better performance when compared with item-based models in identical study populations. The importance of variables in RF and XGBoost appeared to differ from that in item-based models when predicting death within 3 months. The addition of nonconventional factors, such as laboratory data, to the XGBoost model improved its predictive ability for 3-month mortality.

### **Predictive Performance of Models**

Thus far, only a limited number of studies have evaluated the predictive performance of machine learning-based models compared with those of stroke prognostic scores [19,20,23]. All these studies were performed in single-center registries or under specific conditions, such as large vessel occlusion in ischemic stroke. Furthermore, previous studies mainly focused on AUROC for assessing predictive performance, although other metrics, such as measures of calibration, are necessary to fully evaluate the performance of models [38]. This study was conducted using a multicenter registry database and several performance metrics. Our study demonstrated that data-driven models developed using machine learning algorithms can perform reasonably well in predicting the 3-month clinical outcomes of patients with acute ischemic stroke. Generally, data-driven models performed better than conventional prognostic scores when both were compared in identical study populations.

This study also demonstrates that the model performance largely depends on the study populations. The study populations varied in terms of both size and patient characteristics, such as prestroke dependency, time from onset to admission, and use of thrombolytic therapy. The variability in AUROC, AUPRC, and Brier scores between the study populations was as large as that between the models. Moreover, the model performance varied depending on the outcomes to be predicted: AUPRCs were substantially decreased for the prediction of death, which is a less frequent event than the poor functional outcome. These findings underscore the reiterated importance of sample size, the number of outcome events, and data quality of the study cohorts where models are to be developed and validated [25,39,40].

#### Variables in Models

In this study, age, preadmission dependence, and variables related to neurological deficits were identified as important predictors for the prediction of poor functional outcome in both item-based regression models and data-driven models using RF and XGBoost. These are well-known risk factors for poor

```
https://ai.jmir.org/2024/1/e46840
```

functional outcome and are also used for predicting death in stroke prognostic scores [4,5,7]. However, BMI and items related to laboratory data, such as D-dimer, high-sensitivity C-reactive protein, and fibrinogen, were found to be the most important variables for predicting death in RF and XGBoost. Indeed, the association between poststroke clinical outcomes and markers of inflammation and hypercoagulation has become a recent research topic [41,42]. Machine learning algorithms can be a promising tool to identify novel factors to be considered in making prognoses for stroke because they can maximize the use of data without arbitrary assumptions and procedures.

### **Clinical Implications**

The ability of machine learning to derive a model that best fits the data on a given cohort is appealing for making prognoses. Prognostic scores with prespecified items may not fit all cohorts because heterogeneity must exist between study cohorts in race or ethnic groups, general health conditions, socioeconomic status, and health care systems. In addition, stroke prognostic scores are at risk of getting outdated over time, as advances in stroke care continuously improve clinical outcomes in patients with stroke [43,44]. However, our analysis suggests that the 3 conventional prognostic scores can perform sufficiently well in our cohort, despite the fact that the original studies that developed the scores had patients with different medical backgrounds and during different study periods. This finding demonstrates the robustness of outcome prediction using regression models in terms of generalizability. Furthermore, considering nonlinear and interaction effects might not be crucial for outcome prediction after ischemic stroke, as the simple regression models worked well in our study.

Point-based stroke prognostic scores are convenient and helpful for making prompt decisions at the bedside. Generally, prognostic scores comprise only a handful of variables on which information can be obtained easily. This advantage in the practicability of the prognostic scores is important in acute stroke care settings. Machine learning algorithms require more data than conventional prognostic scores to reach acceptable performance levels [39], and the data required by machine learning algorithms to realize better performance, such as laboratory data, may not always be available, although they can improve the predictive performance of models. Therefore, further studies are needed to fully assess the incremental value of machine learning–based models in daily clinical practice.

#### **Strengths and Limitations**

This study has several strengths. We assessed and compared the predictive accuracy of prognostic scores against data-driven models, using information from a multicenter, prospective registry of individuals diagnosed with acute stroke. We were able to use several variables, including laboratory data–related items, owing to the detailed clinical data available in the registry. Moreover, comparisons of models were made using various performance metrics. However, this study has also several limitations. First, the selection of patients may have led to bias, although the inclusion and exclusion criteria were identical to those reported in the original studies of the prognostic scores. Second, there were missing data for the baseline variables and clinical outcomes, which may have also led to selection bias.

XSL•FO RenderX

Third, the possibility of overfitting cannot be completely ruled out, despite the predictive models constituted by the training set being fitted to the test set. Finally, this study included only patients with acute ischemic stroke who were hospitalized in tertiary care centers in a restricted region of Japan. Generalizability should be assessed in other settings and for other diseases.

# Conclusions

This study suggests that data-driven models based on machine learning algorithms can improve predictive performance by using diverse types of variables, such as laboratory data–related items. The clinical outcomes of individual patients can be automatically estimated using machine learning algorithms if a large amount of data can be directly drawn from electronic health records. This possibility of making automated and personalized prognoses is an appealing property of data-driven prediction. However, the arrangement of an appropriate electronic infrastructure is indispensable for enabling data collection, and the development of such infrastructure requires time and cost. It is worth noting that conventional prognostic scores can achieve sufficient performance in making stroke prognoses with only a limited number of variables. In the near future, it seems feasible to explore the improvement of preexisting prognostic scores by incorporating novel predictors identified by machine learning algorithms, given the significant investment necessary to fully use machine learning.

# Acknowledgments

This study was supported by the Japan Society for Promotion of Science KAKENHI (grants JP21H03165, JP21K19648, 21K10330, and JP22K10386) and the Ministry of Health, Labour and Welfare AC Program (grant JPMH21446713). The authors thank all the Fukuoka Stroke Registry investigators and their hospitals for participating in this study and all the clinical research coordinators from the Hisayama Research Institute for Lifestyle Diseases for their help in obtaining informed consent and collecting clinical data. Participating hospitals in the Fukuoka Stroke Registry included Kyushu University Hospital (Fukuoka, Japan), National Hospital Organization Kyushu Medical Center (Fukuoka, Japan), National Hospital Organization Fukuoka-Higashi Medical Center (Koga, Japan), Fukuoka Red Cross Hospital (Fukuoka, Japan), St Mary's Hospital (Kurume, Japan), Steel Memorial Yawata Hospital (Kitakyushu, Japan), and Japan Labor Health and Welfare Organization Kyushu Rosai Hospital (Kitakyushu, Japan). Steering committee and research working group members of the Fukuoka Stroke Registry were Takao Ishitsuka, MD, PhD (Fukuoka Mirai Hospital, Fukuoka, Japan); Setsuro Ibayashi, MD, PhD (Chair, Seiai Rehabilitation Hospital, Onojo, Japan); Kenji Kusuda, MD, PhD (Seiai Rehabilitation Hospital, Onojo, Japan); Kenichiro Fujii, MD, PhD (Japan Seafarers Relief Association Moji Ekisaikai Hospital, Kitakyushu, Japan); Tetsuhiko Nagao, MD, PhD (Safety Monitoring Committee, Seiai Rehabilitation Hospital, Onojo, Japan); Yasushi Okada, MD, PhD (Vice-Chair, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan); Masahiro Yasaka, MD, PhD (National Hospital Organization Kyushu Medical Center, Fukuoka, Japan); Hiroaki Ooboshi, MD, PhD (Fukuoka Dental College Medical and Dental Hospital, Fukuoka, Japan); Takanari Kitazono, MD, PhD (Principal Investigator, Kyushu University, Fukuoka, Japan); Katsumi Irie, MD, PhD (Hakujyuji Hospital, Fukuoka, Japan); Tsuyoshi Omae, MD, PhD (Imazu Red Cross Hospital, Fukuoka, Japan); Kazunori Toyoda, MD, PhD (National Cerebral and Cardiovascular Center, Suita, Japan); Hiroshi Nakane, MD, PhD (National Hospital Organization Fukuoka-Higashi Medical Center, Koga, Japan); Masahiro Kamouchi, MD, PhD (Kyushu University, Fukuoka, Japan); Hiroshi Sugimori, MD, PhD (National Hospital Organization Kyushu Medical Center, Fukuoka, Japan); Shuji Arakawa, MD, PhD (Steel Memorial Yawata Hospital, Kitakyushu, Japan); Kenji Fukuda, MD, PhD (St Mary's Hospital, Kurume, Japan); Tetsuro Ago, MD, PhD (Kyushu University, Fukuoka, Japan); Jiro Kitayama, MD, PhD (Fukuoka Red Cross Hospital, Fukuoka, Japan); Shigeru Fujimoto, MD, PhD (Jichi Medical University, Shimotsuke, Japan); Shoji Arihiro, MD (Japan Labor Health and Welfare Organization Kyushu Rosai Hospital, Kitakyushu, Japan); Junya Kuroda, MD, PhD (National Hospital Organization Fukuoka-Higashi Medical Center, Koga, Japan); Yoshinobu Wakisaka, MD, PhD (Kyushu University Hospital, Fukuoka, Japan); Yoshihisa Fukushima, MD (St Mary's Hospital, Kurume, Japan); Ryu Matsuo, MD, PhD (Secretariat, Kyushu University, Fukuoka, Japan); Fumi Irie, MD, PhD (Kyushu University, Fukuoka, Japan); Kuniyuki Nakamura, MD, PhD (Kyushu University Hospital, Fukuoka, Japan); and Takuya Kiyohara, MD, PhD (Kyushu University Hospital, Fukuoka, Japan).

# **Conflicts of Interest**

None declared.

# **Multimedia Appendix 1**

Stroke prognostic scores. [DOCX File , 36 KB-Multimedia Appendix 1]

# **Multimedia Appendix 2**

Study populations and events based on the criteria of stroke prognostic scores. [DOCX File , 34 KB-Multimedia Appendix 2]



# Multimedia Appendix 3

Rates of missing values. [DOCX File, 38 KB-Multimedia Appendix 3]

# Multimedia Appendix 4

R programs for the development of machine learning–based models. [DOCX File , 33 KB-Multimedia Appendix 4]

# **Multimedia Appendix 5**

Baseline data according to death within 3 months. [DOCX File , 40 KB-Multimedia Appendix 5]

# References

- 1. Jauch EC, Saver JL, Adams Jr HP, Bruno A, Connors JJ, Demaerschalk BM, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. Mar 2013;44(3):870-947. [doi: 10.1161/STR.0b013e318284056a] [Medline: 23370205]
- Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, et al. 2018 guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. Mar 2018;49(3):e46-110. [FREE Full text] [doi: 10.1161/STR.000000000000158] [Medline: 29367334]
- 3. Hallevi H, Barreto AD, Liebeskind DS, Morales MM, Martin-Schild SB, Abraham AT, et al. Identifying patients at high risk for poor outcome after intra-arterial therapy for acute ischemic stroke. Stroke. May 2009;40(5):1780-1785. [FREE Full text] [doi: 10.1161/STROKEAHA.108.535146] [Medline: 19359652]
- Saposnik G, Kapral MK, Liu Y, Hall R, O'Donnell M, Raptis S, et al. IScore: a risk score to predict death early after hospitalization for an acute ischemic stroke. Circulation. Feb 22, 2011;123(7):739-749. [doi: 10.1161/CIRCULATIONAHA.110.983353] [Medline: 21300951]
- Saposnik G, Raptis S, Kapral MK, Liu Y, Tu JV, Mamdani M, et al. The iScore predicts poor functional outcomes early after hospitalization for an acute ischemic stroke. Stroke. Dec 2011;42(12):3421-3428. [doi: 10.1161/STROKEAHA.111.623116] [Medline: 21960583]
- Ntaios G, Faouzi M, Ferrari J, Lang W, Vemmos K, Michel P. An integer-based score to predict functional outcome in acute ischemic stroke: the ASTRAL score. Neurology. Jun 12, 2012;78(24):1916-1922. [doi: 10.1212/WNL.0b013e318259e221] [Medline: 22649218]
- O'Donnell MJ, Fang J, D'Uva C, Saposnik G, Gould L, McGrath E, et al. The PLAN score: a bedside prediction rule for death and severe disability following acute ischemic stroke. Arch Intern Med. Nov 12, 2012;172(20):1548-1556. [doi: 10.1001/2013.jamainternmed.30] [Medline: 23147454]
- Flint AC, Xiang B, Gupta R, Nogueira RG, Lutsep HL, Jovin TG, et al. THRIVE score predicts outcomes with a third-generation endovascular stroke treatment device in the TREVO-2 trial. Stroke. Dec 2013;44(12):3370-3375. [FREE Full text] [doi: 10.1161/STROKEAHA.113.002796] [Medline: 24072003]
- 9. Gao MM, Wang J, Saposnik G. The art and science of stroke outcome prognostication. Stroke. May 2020;51(5):1358-1360. [doi: <u>10.1161/STROKEAHA.120.028980</u>] [Medline: <u>32208841</u>]
- Poldrack RA, Gorgolewski KJ. Making big data open: data sharing in neuroimaging. Nat Neurosci. Nov 2014;17(11):1510-1517. [doi: 10.1038/nn.3818] [Medline: 25349916]
- 11. Shah ND, Steyerberg EW, Kent DM. Big data and predictive analytics: recalibrating expectations. JAMA. Jul 03, 2018;320(1):27-28. [doi: 10.1001/jama.2018.5602] [Medline: 29813156]
- 12. Dreiseitl S, Ohno-Machado L. Logistic regression and artificial neural network classification models: a methodology review. J Biomed Inform. Oct 2002;35(5-6):352-359. [FREE Full text] [doi: 10.1016/s1532-0464(03)00034-0] [Medline: 12968784]
- 13. Obermeyer Z, Emanuel EJ. Predicting the future big data, machine learning, and clinical medicine. N Engl J Med. Sep 29, 2016;375(13):1216-1219. [FREE Full text] [doi: 10.1056/NEJMp1606181] [Medline: 27682033]
- 14. Handelman GS, Kok HK, Chandra RV, Razavi AH, Lee MJ, Asadi H. eDoctor: machine learning and the future of medicine. J Intern Med. Dec 2018;284(6):603-619. [FREE Full text] [doi: 10.1111/joim.12822] [Medline: 30102808]
- Handelman GS, Kok HK, Chandra RV, Razavi AH, Huang S, Brooks M, et al. Peering into the black box of artificial intelligence: evaluation metrics of machine learning methods. AJR Am J Roentgenol. Jan 2019;212(1):38-43. [doi: 10.2214/AJR.18.20224] [Medline: 30332290]
- 16. Ngiam KY, Khor IW. Big data and machine learning algorithms for health-care delivery. Lancet Oncol. May 2019;20(5):e262-e273. [doi: 10.1016/S1470-2045(19)30149-4] [Medline: 31044724]
- 17. Asadi H, Dowling R, Yan B, Mitchell P. Machine learning for outcome prediction of acute ischemic stroke post intra-arterial therapy. PLoS One. Feb 10, 2014;9(2):e88225. [FREE Full text] [doi: 10.1371/journal.pone.0088225] [Medline: 24520356]

- van Os HJ, Ramos LA, Hilbert A, van Leeuwen M, van Walderveen MA, Kruyt ND, et al. Predicting outcome of endovascular treatment for acute ischemic stroke: potential value of machine learning algorithms. Front Neurol. Sep 25, 2018;9:784.
   [FREE Full text] [doi: 10.3389/fneur.2018.00784] [Medline: 30319525]
- 19. Heo J, Yoon JG, Park H, Kim YD, Nam HS, Heo JH. Machine learning-based model for prediction of outcomes in acute stroke. Stroke. May 2019;50(5):1263-1265. [doi: 10.1161/STROKEAHA.118.024293] [Medline: 30890116]
- Nishi H, Oishi N, Ishii A, Ono I, Ogura T, Sunohara T, et al. Predicting clinical outcomes of large vessel occlusion before mechanical thrombectomy using machine learning. Stroke. Sep 2019;50(9):2379-2388. [FREE Full text] [doi: 10.1161/STROKEAHA.119.025411] [Medline: <u>31409267</u>]
- Alaka SA, Menon BK, Brobbey A, Williamson T, Goyal M, Demchuk AM, et al. Functional outcome prediction in ischemic stroke: a comparison of machine learning algorithms and regression models. Front Neurol. 2020;11:889. [FREE Full text] [doi: 10.3389/fneur.2020.00889] [Medline: 32982920]
- Brugnara G, Neuberger U, Mahmutoglu MA, Foltyn M, Herweh C, Nagel S, et al. Multimodal predictive modeling of endovascular treatment outcome for acute ischemic stroke using machine-learning. Stroke. Dec 2020;51(12):3541-3551. [doi: 10.1161/STROKEAHA.120.030287] [Medline: <u>33040701</u>]
- Matsumoto K, Nohara Y, Soejima H, Yonehara T, Nakashima N, Kamouchi M. Stroke prognostic scores and data-driven prediction of clinical outcomes after acute ischemic stroke. Stroke. May 2020;51(5):1477-1483. [doi: 10.1161/STROKEAHA.119.027300] [Medline: 32208843]
- 24. Sirsat MS, Fermé E, Câmara J. Machine learning for brain stroke: a review. J Stroke Cerebrovasc Dis. Oct 2020;29(10):105162. [doi: 10.1016/j.jstrokecerebrovasdis.2020.105162] [Medline: 32912543]
- Christodoulou E, Ma J, Collins GS, Steyerberg EW, Verbakel JY, Van Calster B. A systematic review shows no performance benefit of machine learning over logistic regression for clinical prediction models. J Clin Epidemiol. Jun 2019;110:12-22. [doi: <u>10.1016/j.jclinepi.2019.02.004</u>] [Medline: <u>30763612</u>]
- Gravesteijn BY, Nieboer D, Ercole A, Lingsma HF, Nelson D, van Calster B, et al. Machine learning algorithms performed no better than regression models for prognostication in traumatic brain injury. J Clin Epidemiol. Jun 2020;122:95-107.
   [FREE Full text] [doi: 10.1016/j.jclinepi.2020.03.005] [Medline: 32201256]
- Cowling TE, Cromwell DA, Bellot A, Sharples LD, van der Meulen J. Logistic regression and machine learning predicted patient mortality from large sets of diagnosis codes comparably. J Clin Epidemiol. May 2021;133:43-52. [doi: 10.1016/j.jclinepi.2020.12.018] [Medline: <u>33359319</u>]
- 28. Kamouchi M, Matsuki T, Hata J, Kuwashiro T, Ago T, Sambongi Y, et al. Prestroke glycemic control is associated with the functional outcome in acute ischemic stroke: the Fukuoka Stroke Registry. Stroke. Oct 2011;42(10):2788-2794. [FREE Full text] [doi: 10.1161/STROKEAHA.111.617415] [Medline: 21817134]
- 29. Kumai Y, Kamouchi M, Hata J, Ago T, Kitayama J, Nakane H, et al. Proteinuria and clinical outcomes after ischemic stroke. Neurology. Jun 12, 2012;78(24):1909-1915. [doi: 10.1212/WNL.0b013e318259e110] [Medline: 22592359]
- Quinn TJ, Singh S, Lees KR, Bath PM, Myint PK, VISTA Collaborators. Validating and comparing stroke prognosis scales. Neurology. Sep 05, 2017;89(10):997-1002. [FREE Full text] [doi: 10.1212/WNL.00000000004332] [Medline: 28794250]
- 31. Hoerl AE, Kennard RW. Ridge regression: biased estimation for nonorthogonal problems. Technometrics. Feb 1970;12(1):55-67. [FREE Full text] [doi: 10.1080/00401706.1970.10488634]
- 32. Tibshirani R. Regression shrinkage and selection via the Lasso. J R Stat Soc Series B Stat Methodol. Dec 05, 2018;58(1):267-288. [FREE Full text] [doi: 10.1111/j.2517-6161.1996.tb02080.x]
- 33. Breiman L. Random forests. Mach Learn. 2001;45:5-32. [doi: 10.1023/A:1010933404324]
- 34. Chen TQ, Guestrin C. XGBoost: a scalable tree boosting system. In: Proceedings of the 22nd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining. Presented at: KDD '16; August 13-17, 2016, 2016;785-794; San Francisco, CA. URL: <u>https://dl.acm.org/doi/10.1145/2939672.2939785</u> [doi: <u>10.1145/2939672.2939785</u>]
- Ozenne B, Subtil F, Maucort-Boulch D. The precision--recall curve overcame the optimism of the receiver operating characteristic curve in rare diseases. J Clin Epidemiol. Aug 2015;68(8):855-859. [doi: <u>10.1016/j.jclinepi.2015.02.010</u>] [Medline: <u>25881487</u>]
- 36. Lee SW. Methods for testing statistical differences between groups in medical research: statistical standard and guideline of Life Cycle Committee. Life Cycle. Feb 19, 2022;2:1-8. [FREE Full text] [doi: 10.54724/lc.2022.e1]
- Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent Reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. Ann Intern Med. Jan 06, 2015;162(1):55-63. [FREE Full text] [doi: 10.7326/M14-0697] [Medline: 25560714]
- Steyerberg EW, Vickers AJ, Cook NR, Gerds T, Gonen M, Obuchowski N, et al. Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology. Jan 2010;21(1):128-138. [FREE Full text] [doi: 10.1097/EDE.0b013e3181c30fb2] [Medline: 20010215]
- van der Ploeg T, Austin PC, Steyerberg EW. Modern modelling techniques are data hungry: a simulation study for predicting dichotomous endpoints. BMC Med Res Methodol. Dec 22, 2014;14:137. [FREE Full text] [doi: 10.1186/1471-2288-14-137] [Medline: 25532820]

```
https://ai.jmir.org/2024/1/e46840
```

- 40. Steyerberg EW, Uno H, Ioannidis JP, van Calster B, Collaborators. Poor performance of clinical prediction models: the harm of commonly applied methods. J Clin Epidemiol. Jun 2018;98:133-143. [doi: <u>10.1016/j.jclinepi.2017.11.013</u>] [Medline: <u>29174118</u>]
- 41. Li J, Zhao X, Meng X, Lin J, Liu L, Wang C, et al. High-sensitive C-reactive protein predicts recurrent stroke and poor functional outcome: subanalysis of the clopidogrel in high-risk patients with acute nondisabling cerebrovascular events trial. Stroke. Aug 2016;47(8):2025-2030. [doi: 10.1161/STROKEAHA.116.012901] [Medline: 27328699]
- 42. Hou H, Xiang X, Pan Y, Li H, Meng X, Wang Y. Association of level and increase in D-Dimer with all-cause death and poor functional outcome after ischemic stroke or transient ischemic attack. J Am Heart Assoc. Feb 02, 2021;10(3):e018600. [FREE Full text] [doi: 10.1161/JAHA.120.018600] [Medline: 33412918]
- 43. Phipps MS, Cronin CA. Management of acute ischemic stroke. BMJ. Feb 13, 2020;368:16983. [doi: <u>10.1136/bmj.16983</u>] [Medline: <u>32054610</u>]
- 44. Duncan PW, Bushnell C, Sissine M, Coleman S, Lutz BJ, Johnson AM, et al. Comprehensive stroke care and outcomes: time for a paradigm shift. Stroke. Jan 2021;52(1):385-393. [doi: <u>10.1161/STROKEAHA.120.029678</u>] [Medline: <u>33349012</u>]

### Abbreviations

ASTRAL: Acute Stroke Registry and Analysis of Lausanne AUPRC: area under the precision-recall curve AUROC: area under the receiver operating characteristic curve FSR: Fukuoka Stroke Registry iScore: Ischemic Stroke Predictive Risk Score LASSO: least absolute shrinkage and selection operator PLAN: preadmission comorbidities, level of consciousness, age, and neurologic deficit RF: random forest RR: ridge regression TRIPOD: Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis XGBoost: Extreme gradient boosting

Edited by K El Emam, B Malin; submitted 27.02.23; peer-reviewed by DK Yon, L Boyer; comments to author 13.09.23; revised version received 30.10.23; accepted 04.12.23; published 11.01.24 <u>Please cite as:</u> Irie F, Matsumoto K, Matsuo R, Nohara Y, Wakisaka Y, Ago T, Nakashima N, Kitazono T, Kamouchi M Predictive Performance of Machine Learning–Based Models for Poststroke Clinical Outcomes in Comparison With Conventional Prognostic Scores: Multicenter, Hospital-Based Observational Study JMIR AI 2024;3:e46840 URL: <u>https://ai.jmir.org/2024/1/e46840</u> doi: <u>10.2196/46840</u>

PMID:

©Fumi Irie, Koutarou Matsumoto, Ryu Matsuo, Yasunobu Nohara, Yoshinobu Wakisaka, Tetsuro Ago, Naoki Nakashima, Takanari Kitazono, Masahiro Kamouchi. Originally published in JMIR AI (https://ai.jmir.org), 11.01.2024. This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR AI, is properly cited. The complete bibliographic information, a link to the original publication on https://www.ai.jmir.org/, as well as this copyright and license information must be included.

